Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8209MR)

This product GTTS-WQ8209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8209MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14942MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ6298MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ6445MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ15338MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ6885MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ12306MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ3865MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ6684MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW